Your browser doesn't support javascript.
loading
Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson's Disease, Glioma, and Schwannoma.
Hall, Justin; Prabhakar, Shilpa; Balaj, Leonora; Lai, Charles P; Cerione, Richard A; Breakefield, Xandra O.
Afiliação
  • Hall J; Departments of Chemistry and Chemical Biology and Molecular Medicine, Cornell University, Ithaca, NY, 14853, USA.
  • Prabhakar S; Department of Neurology and Center for Molecular Imaging Research, Department of Radiology, Massachusetts General Hospital and NeuroDiscovery Center, Harvard Medical School, Boston, MA, 02114, USA.
  • Balaj L; Department of Neurology and Center for Molecular Imaging Research, Department of Radiology, Massachusetts General Hospital and NeuroDiscovery Center, Harvard Medical School, Boston, MA, 02114, USA.
  • Lai CP; Department of Neurology and Center for Molecular Imaging Research, Department of Radiology, Massachusetts General Hospital and NeuroDiscovery Center, Harvard Medical School, Boston, MA, 02114, USA.
  • Cerione RA; Department of Neurology and Center for Molecular Imaging Research, Department of Radiology, Massachusetts General Hospital and NeuroDiscovery Center, Harvard Medical School, Boston, MA, 02114, USA.
  • Breakefield XO; Institute of Biomedical Engineering, National Tsing Hua University, Hsinchu, 30013, Taiwan.
Cell Mol Neurobiol ; 36(3): 417-27, 2016 Apr.
Article em En | MEDLINE | ID: mdl-27017608
ABSTRACT
Extracellular vesicles present an attractive delivery vehicle for therapeutic proteins. They intrinsically contain many proteins which can provide information to other cells. Advantages include reduced immune reactivity, especially if derived from the same host, stability in biologic fluids, and ability to target uptake. Those from mesenchymal stem cells appear to be intrinsically therapeutic, while those from cancer cells promote tumor progression. Therapeutic proteins can be loaded into vesicles by overexpression in the donor cell, with oligomerization and membrane sequences increasing their loading. Examples of protein delivery for therapeutic benefit in pre-clinical models include delivery of catalase for Parkinson's disease to reduce oxidative stress and thus help neurons to survive; prodrug activating enzymes which can convert a prodrug which crosses the blood-brain barrier into a toxic chemotherapeutic drug for schwannomas and gliomas; and the apoptosis-inducing enzyme, caspase-1 under a Schwann cell specific promoter for schwannoma. This therapeutic delivery strategy is novel and being explored for a number of diseases.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Neoplasias Encefálicas / Proteínas Recombinantes / Sistemas de Liberação de Medicamentos / Vesículas Extracelulares / Glioma / Neurilemoma Limite: Animals / Humans Idioma: En Revista: Cell Mol Neurobiol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Neoplasias Encefálicas / Proteínas Recombinantes / Sistemas de Liberação de Medicamentos / Vesículas Extracelulares / Glioma / Neurilemoma Limite: Animals / Humans Idioma: En Revista: Cell Mol Neurobiol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos